Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Soleno Therapeutics
Redwood City, California, United Statessoleno.life ↗
- Ownership
- Public · SLNO
- Employees
- ~92
- Development stage
- Other
01
Overview
Soleno’s lead program, VYKAT XR (diazoxide choline extended-release tablets; formerly DCCR), received FDA approval in April 2025 for the treatment of hyperphagia associated with Prader-Willi syndrome in adults and children aged four years and older. The company has initiated commercial launch activities in the U.S., with over 268 patient start forms received within weeks of launch. A Marketing Authorization Application to the European Medicines Agency for DCCR/VYKAT XR was planned for Q2 2025[6]. Clinical data presented at ISPOR 2025 highlighted significant reductions in hyperphagia and favorable safety outcomes[8].
- Therapeutic areas
- Rare DiseasesEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
None disclosed as major pharmaceutical or biotech partnerships as of June 2025.
Beyond the preview
Go deeper on Soleno Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Soleno Therapeutics.